FSD Pharma Inc Class B

About FSD Pharma Inc Class B

FSD Pharma Inc. Class B (NASDAQ:HUGE) is focused on developing innovative therapies for the treatment of inflammatory diseases. The company is involved in cutting-edge pharmaceutical research, aiming to bring efficient and cost-effective drugs to market. One of its primary projects is Lucid-MS, a treatment for multiple sclerosis. FSD's goal is to leverage its research capabilities and pharmaceutical expertise to address unmet medical needs and improve patient outcomes.

What is FSD Pharma Inc Class B known for?

Snapshot

2008

Year founded

Employees

Toronto, Canada

Head office

Loading Map...

Operations

All Locations

Toronto, CA

Products and/or services of FSD Pharma Inc Class B

Phase 2 clinical trial of FSD201 for the treatment of COVID-19, aimed at addressing inflammatory disorders.
Psychedelics R&D aimed at exploring novel treatments for mental health disorders, including depression and PTSD.
Cannabinoid-based pharmaceuticals research focusing on innovative treatments for pain management and other inflammatory conditions.
Strategic collaboration with other biotech firms to co-develop groundbreaking therapies for various diseases.
Acquisition and investment in biotech companies to expand research and development capabilities.
Development of ultramicro PEA molecules targeting chronic inflammatory diseases, promoting advanced therapeutic solutions.